Pulmocide

London, United Kingdom · Founded 2007 · Privately Held (backing)

Developer of antifungal drugs designed to treat acute and chronic respiratory diseases. Pulmocide is based in London, United Kingdom and was founded in 2007. Its last reported valuation was $292 million in Sep 2025. It has raised $268 million.

Last reported valuation
$291.6M
Oct 2026
Priced at
—
Total raised
$267.6M
Last round
—

Who backs Pulmocide?

15 investors
InvestorType
F-Prime CapitalVenture capital
Eight RoadsAsset manager
Johnson & Johnson JJDCVenture capital
SV Health InvestorsVenture capital
SR One Capital ManagementOther
Vivo CapitalVenture capital
Pictet Alternative AdvisorsAsset manager
Imperial College London EndowmentOther
Adjuvant Capital—
Asahi Kasei Corporate Venture Capital—
+ 5 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Pulmocide investors

15 investors are on record for Pulmocide, including F-Prime Capital, Eight Roads, Johnson & Johnson JJDC and SV Health Investors. By type, the record holds 4 venture capital firms and 2 asset managers.

Free account
More of Pulmocide with a free account
  • ·The complete investor list: 15 names
  • ·Watch Pulmocide: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 15 firms already write checks for companies like Pulmocide. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View